The best oncology assets draw a crowd and a price to match. Bayer's answer is a courtship, not an auction: it gets to know the founders years before there's a deal, and stays in touch even after a no.
More than 30 candidates are chasing hypertension, high Lp(a), and dyslipidemia, markets far larger than the rare diseases that built the field. Whether it works turns on outcomes trials over the next two to four years, and on pricing.
Health Canada is offering sponsors a no-fault inspection before the new ICH GCP guideline goes into effect, and the bid reveals how regulatory oversight is becoming something of a recruiting tool.
A challenger in liver disease, a cancer head-to-head, and a biosimilar bet on doing the extra work. Each is wagering that the trial, not the head start, decides who wins.
Many of the assets came out of Chinese labs, and much of the money behind them rides on science still years from proving out.
Two would-be contenders answered the same question this week, how to stay relevant when you are not the United States, and they answered it in different currencies: one in words, one in yen.
The FTC has told a federal appeals court that what J&J did to competition matters more than what it meant to do. That, along with a big recent Takeda verdict, should change how you think about every defensive patent move.
Who, and what, gets trusted with the next decade of drug discovery. The answers, so far: an AI résumé, and in China, a shrug.
Money is everywhere and buyers are hungry, so biotechs are seeing several suitors at once and in no rush to commit. The complications: the most wanted assets keep turning up in China, and a US pricing rule means no deal abroad stays abroad.
Christophe Weber leaves a global top-ten drugmaker, and the debt it took to get there. The verdict now belongs to the executive who arrived in the very transaction that made it.
Psychedelics produce their best clinical readout yet, while chip-making juggernaut NVIDIA turns its gaming fortunes into a pharma play.
